Drug Profile
Research programme: injectable allergy therapy - ALK-Abello/Maxygen
Alternative Names: Maxy 20 research programme; Maxy 320Latest Information Update: 31 Jan 2007
Price :
$50
*
At a glance
- Originator Maxygen
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Hypersensitivity; Seasonal allergic rhinitis
Most Recent Events
- 31 Jan 2007 Discontinued - Preclinical for Allergic asthma in Denmark (Injection)
- 31 Jan 2007 Discontinued - Preclinical for Allergic asthma in USA (Injection)
- 31 Jan 2007 Discontinued - Preclinical for Allergy in Denmark (Injection)